Signatures of Immune Reprogramming in Anti-Cd52 Therapy of MS: Markers for Risk Stratification and Treatment Response
Neurological Research and Practice
doi 10.1186/s42466-019-0045-x
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Springer Science and Business Media LLC